Abstract

Background: There is a paucity of evidence to inform the value of pharmacogenomic (PGx) results in patients after kidney transplant and how these results differ between Indigenous Americans and Whites. This study aims to identify the frequency of recommended medication changes based on PGx results and compare the pharmacogenomic (PGx) results and patients' perceptions of the findings between a cohort of Indigenous American and White kidney transplant recipients.

Methods: Thirty-one Indigenous Americans and fifty White kidney transplant recipients were studied prospectively. Genetic variants were identified using the OneOme RightMed PGx test of 27 genes. PGx pharmacist generated a report of the genetic variation and recommended changes. Pre- and post-qualitative patient surveys were obtained.

Results: White and Indigenous American subjects had a similar mean number of medications at the time of PGx testing (mean 13 (SD 4.5)). In the entire cohort, 53% received beta blockers, 30% received antidepressants, 16% anticoagulation, 47% pain medication, and 25% statin therapy. Drug-gene interactions that warranted a clinical action were present in 21.5% of patients. In 12.7%, monitoring was recommended. Compared to the Whites, the Indigenous American patients had more normal CYP2C19 (p = 0.012) and CYP2D6 (p = 0.012) activities. The Indigenous American patients had more normal CYP4F2 (p = 0.004) and lower VKORC (p = 0.041) activities, phenotypes for warfarin drug dosing, and efficacy compared to the Whites. SLC6A4, which affects antidepressant metabolism, showed statistical differences between the two cohorts (p = 0.017); specifically, SLC6A4 had reduced expression in 45% of the Indigenous American patients compared to 20% of the White patients. There was no significant difference in patient perception before and after PGx.

Conclusions: Kidney transplant recipients had several drug-gene interactions that were clinically actionable; over one-third of patients were likely to benefit from changes in medications or drug doses based on the PGx results. The Indigenous American patients differed in the expression of drug-metabolizing enzymes and drug transporters from the White patients.

Keywords: Indigenous population; drug-metabolizing enzymes; genotype; kidney transplantation; pharmacogenetics; pharmacogenomics; phenotype; polymorphism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the study’s design; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

References

1. Relling M.V., Evans W.E. Pharmacogenomics in the clinic. Nature. 2015;526:343–350. doi: 10.1038/nature15817. - DOI - PMC - PubMed
2. Salvadori M., Tsalouchos A. Pharmacogenetics of immunosuppressant drugs: A new aspect for individualized therapy. World J. Transplant. 2020;10:90–103. doi: 10.5500/wjt.v10.i5.90. - DOI - PMC - PubMed
3. Birdwell K. Role of pharmacogenomics in dialysis and transplantation. Curr. Opin. Nephrol. Hypertens. 2014;23:570–577. doi: 10.1097/MNH.0000000000000065. - DOI - PMC - PubMed
4. Adams S.M., Crisamore K.R., Empey P.E. Clinical Pharmacogenomics: Applications in Nephrology. Clin. J. Am. Soc. Nephrol. 2018;13:1561–1571. doi: 10.2215/CJN.02730218. - DOI - PMC - PubMed
5. Collins F.S., Varmus H. A new initiative on precision medicine. N. Engl. J. Med. 2015;372:793–795. doi: 10.1056/NEJMp1500523. - DOI - PMC - PubMed

Show all 40 references

Related information

• MedGen

Grants and funding

This research was supported by an intra-mural fund from the Mayo Clinic Center for Individualized Medicine Clinomics-Pharmacogenomics funding program. This fund provided up to 100 PGx tests and PGx-pharmacist analysis and interpretation and covered statistical support.

LinkOut - more resources

• Full Text Sources
• Europe PubMed Central
• MDPI
• PubMed Central